Carrageenan
Based on 1 publication(s) in Google Scholar
Carrageenan is an antiviral and anticancer agent. Carrageenan inhibits herpes simplex virus (HSV), HIV, and hepatitis A virus (HAV) by directly binding to the viral capsid to block the attachment of viruses such as HPV to HSPG factors on the cell surface. Carrageenan delays and arrests cell cycle progression, exhibits cytotoxicity against HeLa cancer cells, and can be applied to studies related to cervical cancer, genital warts, hepatitis A, and other conditions. Carrageenan also induces acute non-immune inflammation, triggers a three-phase inflammatory response involving the release of multiple proinflammatory mediators, and causes persistent edema, hyperalgesia, and neutrophil recruitment in mice.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 9000-07-1
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Carrageenan
More
Actividad biológica
ι-carrageenan (HY-W145523), λ-carrageenan (HY-N9470) and κ-carrageenan (HY-138962) (20-1000 μg/mL; 3-15 d) show no significant cytotoxicity against PLC/PRF/5 cells at concentrations up to 200 μg/mL. Among them, the cytotoxicity thresholds (cell viability CD50 >1000 μg/mL) of ι-carrageenan and λ-carrageenan are higher than that of κ-carrageenan (cell viability CD50=732.1 μg/mL)[2].
ι-carrageenan, λ-carrageenan, and κ-carrageenan (0.5-200 μg/mL; 15 d) potently inhibit the expression of HAV antigen in PLC/PRF/5 cells in a concentration-dependent manner in vitro, among which ι-carrageenan (ED50=2.5 μg/mL) exhibits the strongest activity, followed by λ-carrageenan (ED50=4.5 μg/mL) and κ-carrageenan (ED50=100.3 μg/mL); meanwhile, they also reduce the replication and infectivity of HAV in PLC/PRF/5 cells in a concentration-dependent manner[2].
κ-carrageenan and λ-carrageenan (250-2500 μg/mL; 72 h) exhibit moderate concentration-dependent cytotoxicity against HeLa cells, with λ-carrageenan (IC50=475 μg/mL) showing stronger activity than κ-carrageenan (IC50=550.8 μg/mL); in addition, λ-carrageenan also exerts a strong concentration-dependent antiproliferative effect and reduces cell confluence[3].
κ-carrageenan (250-2500 μg/mL; 72 h) induces concentration-dependent G2/M phase arrest in HeLa-FUCCI cells, whereas λ-CO does not alter the proportion of each cell cycle phase in HeLa-FUCCI cells[3].
κ-carrageenan and λ-carrageenan (250-2500 μg/mL; 72 h) show no significant cytotoxicity against HUVEC at concentrations up to 2500 μg/mL, and do not increase the mortality of HUVEC cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HeLa
-
Concentration:250-2500 μg/mL
-
Incubation Time:72 h
-
Result:Increased dead cell percentage in a dose-dependent manner (k-CO).
Increased dead cell percentage in a dose-dependent manner and reduced cell confluence in a concentration-dependent manner (λ-CO).
-
Cell Line:HeLa-FUCCI
-
Concentration:250-2500 μg/mL
-
Incubation Time:72 h
-
Result:Caused a concentration-dependent increase in the ratio of cells arrested in the G2/M phase, with a linear correlation between concentration and G2/M phase cell ratio (k-CO).
Showed no significant difference in cell cycle phase ratios compared to untreated cells (λ-CO).
Carrageenan (1% (w/v); s.c.; plantar region of the left hind paw) at an injection volume of 100 μL induces acute paw edema in male Wistar rats (with the peak edema volume reached 4-5 hours post-injection), while an injection volume of 25 μL induces acute paw edema in male Swiss albino mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss mice (male, 30-35 g); C57/BL6 mice (male, 30-35 g); TNF-α p55 receptor knockout mice (C57/BL6 background, male, 30-35 g)[4]
-
Dosage:300 μg per paw
-
Administration:s.c.; single injection
-
Result:Induced a biphasic paw oedema (peaks at 6 and 72 hours) in Swiss and C57/BL6 mice, which resolved by 96 hours.\n
Caused sustained mechanical allodynia, detectable as early as 1 hour post-injection and persisting for up to 72 hours, with similar response frequencies in Swiss and C57/BL6 mice.\n
Increased MPO activity in paw tissue by ~10-fold at 6 hours post-injection in Swiss and C57/BL6 mice.\nReduced paw oedema by 89% at 6 hours and 50% at 48 hours in TNF-α p55 receptor knockout mice.\n
Reduced mechanical allodynia by 39% at 6 hours, 37% at 24 hours, and 25% at 48 hours in TNF-α p55 receptor knockout mice.\n
Reduced MPO activity by 51% at 6 hours in TNF-α p55 receptor knockout mice.
-
Animal Model:Wistar (male, 165-220 g) and Albino Swiss (male, 25-35 g)[5]
-
Dosage:100 μL of 1% (w/v), 25 μL of 1% (w/v)
-
Administration:s.c. into plantar region of left hind paw; single dose
-
Result:Induced acute paw edema, with paw volume increasing to a maximum of ~2.2 mL at 4-5 hours post-injection, then decreasing to ~1.8 mL by 24 hours post-injection.
Induced acute paw edema, with plethysmometry used to quantify volume changes over the 24-hour period.
Chemical Information
-
No. CAS 9000-07-1
-
Appearance Solid
-
Color White to off-white
-
SMILES
[Carrageenan]
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Inflammopharmacology
The sesquiterpene lactone components of Cichorium glandulosum suppress both in vitro and in vivo inflammatory responses by reducing IL-1β levels. [Abstract]2025 Dec 2. PMID: 41329398
Solvente y solubilidad
H2O : 3.33 mg/mL (ultrasonic and warming and heat to 60°C)
Pureza y Documentación
-
Ficha de datos (279 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Buck CB, et al. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog. 2006;2(7):e69. [Content Brief]
[2]. Girond S, et al. Antiviral activity of carrageenan on hepatitis A virus replication in cell culture. Res Virol. 1991;142(4):261-270. [Content Brief]
[3]. Prasedya ES, et al. Carrageenan delays cell cycle progression in human cancer cells in vitro demonstrated by FUCCI imaging. BMC Complement Altern Med. 2016;16:270. Published 2016 Aug 4. [Content Brief]
[4]. Rocha AC, et al. Relevance of tumour necrosis factor-alpha for the inflammatory and nociceptive responses evoked by carrageenan in the mouse paw. Br J Pharmacol. 2006;148(5):688-695. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Carrageenan Related Classifications
HY-125474 Related Classifications
Powered by Bioz